<DOC>
	<DOCNO>NCT01662037</DOCNO>
	<brief_summary>Bosentan kind dual endothelin receptor antagonist.The purpose study investigate Bosentan therapy modify outcome child functional single ventricle .</brief_summary>
	<brief_title>Bosentan Therapy Children With Functional Single Ventricle</brief_title>
	<detailed_description>Increased pulmonary vascular resistance ( PVR ) serous issue child functional single ventricle stag operative period . The purpose study investigate Bosentan therapy improve survival life quality stag Fontan procedure child high risk increase PVR .</detailed_description>
	<mesh_term>Heart Defects , Congenital</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>Signed informed consent obtain patient 's legally acceptable representative . Pediatric patient wait stag Fontan procedure high risk increase PVR bidirectional cavopulmonary connection ( BCPC ) Transpulmonary pressure gradiant ( TPG ) &gt; 10mmHg obstruction anastomosis lung problem exclude . With diagnosis high risk increase PVR , associate TAPVC , pulmonary artery banding , systemic pulmonary shunt 6 month , et al . Diagnosed increase PVR catheterization . PAH associate condition mention , e.g. , iPAH , PAH secondary portal hypertension , HIV patient opportunistic infection Psychotic , addictive disorder limit ability provide inform consent comply study requirement AST and/or ALT &gt; 3 time upper limit normal range . Hemoglobin concentration &lt; 75 % low limit normal range Treatment plan treatment another investigational drug within 3 month screen Treatment calcineurininhibitors ( e.g. , cyclosporine A tacrolimus ) , fluconazole , glibenclamide ( glyburide ) within 1 week enrollment study Known hypersensitivity bosentan excipients</criteria>
	<gender>All</gender>
	<minimum_age>4 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Pulmonary vascular resistance</keyword>
	<keyword>Heart defect , Congenital</keyword>
	<keyword>Receptors , endothelin</keyword>
	<keyword>Bosentan</keyword>
</DOC>